News
Injectable medications originally developed for the treatment of diabetes are also effective for weight loss, and have surged ...
U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...
12h
Zacks Small Cap Research on MSNMTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%…(NASDAQ:MTVA) announced positive results from the Phase 1 Part 2 multiple ascending dose (MAD) trial of DA-1726 in obesity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results